Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2015—Roche received FDA approval for the Cobas HBV and Cobas HCV viral load tests for use on the Cobas 6800 and Cobas 8800 systems. Cobas HBV is a real-time PCR test designed to offer an expanded linear range coupled with broad coverage of all known HBV genotypes (A–H), including pre-core mutations with improved sensitivity.
December 2015—DeNovo Sciences announced that the company will operate under the name Celsee Diagnostics, effective immediately.
December 2015—American Medical Technologists announced the approval of the AMT Medical Technologist (MT) exam by the California Department of Public Health, Laboratory Field Services.
December 2015—Luminex received CE-IVD marking for its NxTAG Respiratory Pathogen Panel. The panel detects 21 clinically relevant viral and bacterial respiratory pathogens, including the atypical bacteria Chlamydophila pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila.
December 2015—New England Biolabs released its NEBNext Ultra II DNA Library Prep Kit for Illumina next-generation sequencing systems. The reagents for each step in the library preparation workflow have been reformulated to enable high-yield preparation—from a variety of sample types, including formalin-fixed, paraffin-embedded samples—of high-quality libraries, from 500 picograms to 1 microgram of input DNA.
December 2015—Diagnostica Stago launched its next-generation ecarin-based chromogenic assay for dabigatran, STA-ECA II. Fully automated with barcoded loading on Stago’s high throughput analyzers, STA-ECA II enables laboratories to measure dabigatran (Pradaxa) in plasma samples and is insensitive to lupus anticoagulants and heparin along with coagulation factor and fibrinogen levels.
December 2015—Dako announced FDA approval of a test that can identify PD-L1 expression levels on the surface of non-small cell lung cancer tumor cells and provide information on the survival benefit with Opdivo (nivolumab) for patients with nonsquamous NSCLC.
December 2015—Inova Diagnostics announced the FDA clearance of Quanta Flash CCP3, an assay that aids in the diagnosis of rheumatoid arthritis. The fully automated chemiluminescent assay, which has demonstrated excellent clinical performance in large cohorts of RA and disease control patients, uses a third-generation cyclic citrullinated peptide technology from Inova Diagnostics.
December 2015—Irvine Scientific released BalanCD Transfectory CHO, a cell culture medium for rapid, scalable production of recombinant proteins through transient transfection in CHO cells. The medium is chemically defined and animal component free and is designed to support sustained, high growth with increased transfection efficiency that can yield gram-scale protein expression.
December 2015—Rheonix raised $28.6 million to further expand the company’s commercialization efforts for its molecular testing platforms, the Encompass MDx and Encompass Optimum.
